Immune checkpoint inhibitor (keytruda, opdivo, yervoy, tecentriq, imfinzi, libtayo) denied for missing prior authorization by UnitedHealthcare?

UnitedHealthcare covers immune checkpoint inhibitors (Keytruda/pembrolizumab, Opdivo/nivolumab, Yervoy/ipilimumab, Tecentriq/atezolizumab, Imfinzi/durvalumab, Libtayo/cemiplimab, and related agents) under the medical benefit when prescribed for cancer indications. This policy provides parameters for coverage of injectable oncology medications, including therapeutic radiopharmaceuticals, covered under the medical benefit based upon the National Comprehensive Cancer Network (NCCN) Drugs & Biologics Compendium, which lists appropriate drugs and biologics for specific cancers using US Food and Drug Administration (FDA)-approved disease indications and specific NCCN panel recommendations. UnitedHealthcare recognizes indications listed in the NCCN Drugs and Biologics Compendium with Categories of Evidence and Consensus of 1, 2A, and 2B as proven and medically necessary, and Category 3 as unproven and not medically necessary. Coverage is provided for the UnitedHealthcare preferred oncology product contingent on the diagnosis-specific criteria; coverage for any non-preferred product is contingent on both the Preferred Product Criteria and Diagnosis-Specific Criteria, and members new to therapy are required to use the preferred product unless they meet exception criteria. Preferred/non-preferred designations vary by indication—for example, in non-small cell lung cancer Keytruda Qlex is preferred; in head and neck cancers Keytruda Qlex is non-preferred; and in squamous cell skin cancer Libtayo is preferred while Keytruda, Keytruda Qlex, Opdivo, Opdivo Qvantig, and Unloxcyt are non-preferred. To qualify for a non-preferred product, the patient must have a history of intolerance or contraindication to a UnitedHealthcare preferred oncology product, and the physician must attest that the same intolerance, contraindication, or adverse event would not be expected with the non-preferred product. Keytruda is administered through the medical benefit but specialty pharmacy distribution is required: UnitedHealthcare classifies Keytruda as a specialty medication requiring prior authorization through OptumRx, typically placed on a high-cost specialty tier (Tier 5). Prior authorization is required, with reauthorization on a periodic basis, and specific PD-L1 expression thresholds (e.g., ≥50% for monotherapy first-line NSCLC) apply per the NCCN/FDA labels referenced in the policy.

- **Cite NCCN Category 1/2A recommendation for the exact indication**: UHC's own policy binds coverage to NCCN Compendium recommendations of Category 1, 2A, or 2B as proven and medically necessary . Quote the specific NCCN guideline page and category (e.g., NCCN NSCLC Guidelines list pembrolizumab + chemo as Category 1 for first-line metastatic non-squamous NSCLC; KEYNOTE-189 trial). - **Reference pivotal trial data supporting the FDA label**: For Keytruda in NSCLC cite KEYNOTE-024 (PD-L1 ≥50% monotherapy) and KEYNOTE-189/407 (combo with chemo); for Opdivo+Yervoy cite CheckMate-227/9LA; for Libtayo cite EMPOWER-Lung-1 and EMPOWER-CSCC-1; for Imfinzi cite PACIFIC (stage III NSCLC after chemoradiation); for Tecentriq cite IMpower150/133. - **Document preferred-product step therapy was met or is contraindicated**: Provide chart notes showing prior trial of the UHC preferred ICI with progression, intolerance, or a contraindication (e.g., active autoimmune disease, hypersensitivity), satisfying UHC's exception pathway as history of intolerance or contraindication to one of the UnitedHealthcare's preferred oncology products, and physician attests that the same intolerance, contraindication, or adverse event would not be expected to occur with the respective non-preferred product. - **Submit biomarker results**: Attach the PD-L1 IHC report (22C3/SP263), MSI/MMR or TMB testing report, and tumor histology confirming the FDA-labeled indication; for monotherapy NSCLC confirm PD-L1 expression positive ≥ 50% . - **Invoke ASCO and NCCN consensus**: ASCO Clinical Practice Guidelines (e.g., ASCO/ESMO guidelines for metastatic NSCLC, melanoma, RCC, HNSCC, urothelial carcinoma) concur with NCCN on ICI use; cite specific guideline year and recommendation grade. - **Cite UHC's medical-benefit step therapy carve-outs**: Continuation-of-therapy provisions apply when the member has been receiving the ICI; reference continuation of prior therapy within the past 365 days as grounds for approval without re-trying the preferred agent. - **Escalate to external/independent review with policy language**: Per practitioner experience, external reviews succeed when patients include a detailed timeline showing how UnitedHealthcare's denial contradicts their own published criteria, and independent medical reviewers appreciate clear, point-by-point rebuttals that reference the plan's policy language directly.

## Why UHC Requires Prior Authorization for Checkpoint Inhibitors — and How to Appeal a Denial

UnitedHealthcare requires prior authorization (PA) for immune checkpoint inhibitors — pembrolizumab (Keytruda), nivolumab (Opdivo), ipilimumab (Yervoy), atezolizumab (Tecentriq), durvalumab (Imfinzi), and cemiplimab (Libtayo) — because these are high-cost specialty oncology agents with multiple distinct FDA-approved indications, many of which are biomarker-gated. A PA denial typically means the submitted documentation did not satisfy one or more criteria in UHC's clinical coverage determination policy, or that a required companion diagnostic result was missing, ambiguous, or not linked to the correct FDA-approved indication.

## Why This Denial Is Appealable

PA denials are not final. They are the start of a structured appeal process that, if navigated correctly, results in overturn in a significant proportion of oncology cases. UHC's denial notice must identify the specific criterion that was not met. If it does not, request the full written clinical rationale and the coverage policy applied. Under ERISA §503, self-funded employer plans must provide a full and fair review. Under ACA §2719, insured plans must allow independent external review after internal exhaustion. External reviewers — independent oncologists — evaluate whether UHC's clinical criteria were correctly applied.

## Federal Appeal Framework

• Internal appeal: File within the deadline on your denial notice — typically 180 days for non-urgent pre-service denials. UHC must decide standard pre-service appeals within 30 days.
• Expedited review: If treatment is urgent or ongoing, request expedited internal review (72-hour decision) and simultaneously request external review.
• External review (ACA §2719): After one internal denial (or if UHC fails to decide in time), escalate to independent external review. Request a reviewer with oncology credentials matched to your tumor type.
• State insurance department: File a parallel complaint at any stage.
• Four-month window: From the first denial, you typically have approximately four months of combined internal and external review opportunity before rights expire — start your appeal promptly.

## Documentation to Gather

• Complete pathology and staging report: Tumor type, histology, molecular subtype, and stage — exactly matching the FDA-approved indication for the requested agent.
• Companion diagnostic / biomarker result: If the FDA approval is biomarker-gated, the lab report confirming the result is required. Confirm with your oncologist which result applies to the specific agent and indication.
• Line-of-therapy documentation: Treatment summary with dates showing prior therapies, responses, and outcomes — establishing the correct line of therapy.
• Oncologist letter of medical necessity: Citing the FDA-approved indication (with label section attached), the applicable NCCN guideline recommendation category, the specific clinical rationale for this patient, and why alternatives are inadequate.
• Performance status and organ function: Chart notes documenting clinical parameters relevant to UHC's criteria.
• UHC clinical coverage policy: Request the exact policy applied and build your appeal to address every criterion listed.

## Criteria-Mapping Structure

| UHC PA Criterion | Your Documentation | |---|---| | Confirmed tumor type + histology | Pathology report | | Biomarker/companion diagnostic result | Lab report | | Correct line of therapy documented | Treatment summary | | FDA-approved indication matched | Label indication section attached | | NCCN recommendation category | Oncologist letter | | Performance status documented | Chart note | | No adequate covered alternative | Oncologist letter addressing alternatives |